Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

645
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
645
Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

23
Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
23
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

1.3K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.3K
Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

676
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
676
Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations01:19

Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations

46
The pathophysiology of Acute Coronary Syndrome [ACD] involves several key processes:The main underlying cause of ACD is atherosclerosis, a chronic inflammatory disease characterized by the buildup of lipid-laden plaques within the coronary arteries.As the atherosclerotic plaque grows in the coronary artery, it may become unstable due to the formation of a lipid-rich core and a thin fibrous cap. Inflammatory cells within the plaque, such as macrophages, secrete enzymes that degrade the...
46
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

22
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
22

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Automated AI-Based Aortic Measurements From Attenuation Correction CT as an Adjunctive Cardiovascular Risk Biomarker: An International Multicenter Study.

Circulation. Cardiovascular imaging·2026
Same author

GLP-1-Based Therapies in Type 1 Diabetes: Emerging Evidence on Cardiovascular, Renal, and Safety Outcomes.

Diabetes, obesity & metabolism·2026
Same author

UNICORN During Transcatheter Aortic Valve Replacement in Native and Bioprosthetic Aortic Valves: A Multicenter Study.

JACC. Cardiovascular interventions·2026
Same author

Functional mitral valve regurgitation outcomes by treatment modality: a systematic review and meta-analysis of reconstructed survival data.

BMC cardiovascular disorders·2026
Same author

Optimal Antithrombotic Therapy for Peripheral Artery Disease: A Systematic Review and Network Meta-Analysis.

Journal of the American Heart Association·2026
Same author

Authors' reply: Myasthenia gravis following the initiation of statin therapy.

Journal of internal medicine·2026
Same journal

Long-Term Outcomes of Glucagon-Like Peptide-1 Receptor Agonists in Patients With Peripheral Artery Disease and Type 2 Diabetes.

Journal of the American Heart Association·2026
Same journal

Stable, Progressive, and Acute Valve Syndrome in Severe Aortic Stenosis: Insights from the CURRENT AS Registry-2.

Journal of the American Heart Association·2026
Same journal

<i>LPA</i> Kringle IV Type-2 Genetic Variants Are Associated With Apolipoprotein (a) Size, Hypertension, and Nonfasting Glucose Levels.

Journal of the American Heart Association·2026
Same journal

Hemorrhagic Transformation Mediates Stress Hyperglycemia Effect on Functional Outcome in Minor Ischemic Stroke.

Journal of the American Heart Association·2026
Same journal

Mental Disorders After Cardiac Implantable Electronic Device Implantation in Young Individuals.

Journal of the American Heart Association·2026
Same journal

Hypertensive Disorders of Pregnancy Associated With Cerebral Small Vessel Disease Decades Later.

Journal of the American Heart Association·2026
See all related articles

Related Experiment Video

Updated: Sep 10, 2025

Microfluidics in Assessing Platelet Function
06:47

Microfluidics in Assessing Platelet Function

Published on: November 8, 2024

1.0K

Ticagrelor Paradox: Systematic Review and Network Meta-Analysis.

Atsuyuki Watanabe1, Tadao Aikawa2, Yoshihisa Miyamoto3

  • 1Department of Medicine, Mount Sinai Morningside and West Icahn School of Medicine at Mount Sinai New York NY USA.

Journal of the American Heart Association
|August 23, 2025
PubMed
Summary
This summary is machine-generated.

The landmark PLATO trial significantly influenced guidelines for acute coronary syndrome treatment, favoring ticagrelor over clopidogrel. However, this analysis questions PLATO

Keywords:
acute coronary syndromeclinical trialdual antiplatelet therapyguideline

More Related Videos

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

83.8K
Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
28:13

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

Published on: February 26, 2013

33.5K

Related Experiment Videos

Last Updated: Sep 10, 2025

Microfluidics in Assessing Platelet Function
06:47

Microfluidics in Assessing Platelet Function

Published on: November 8, 2024

1.0K
The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

83.8K
Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
28:13

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

Published on: February 26, 2013

33.5K

Area of Science:

  • Cardiology
  • Pharmacology
  • Clinical Trials

Background:

  • Current guidelines recommend ticagrelor and prasugrel over clopidogrel for acute coronary syndrome, based on PLATO and TRITON-TIMI 38 trials.
  • Subsequent studies have questioned the reproducibility of ticagrelor's benefits reported in the PLATO trial.

Purpose of the Study:

  • To assess the impact of the PLATO trial on synthesized risk estimates for dual antiplatelet therapies.
  • To compare network meta-analyses of ticagrelor, prasugrel, and clopidogrel with and without the inclusion of PLATO data.

Main Methods:

  • A systematic review and meta-analysis of randomized trials comparing aspirin plus clopidogrel, prasugrel, or ticagrelor.
  • Network meta-analyses were constructed both including and excluding the PLATO trial data.
  • Outcomes assessed included major adverse cardiovascular events, mortality, myocardial infarction, stent thrombosis, and bleeding events.

Main Results:

  • Twelve trials with 52,415 patients were included.
  • Analyses including the PLATO trial showed significantly lower hazard ratios for ticagrelor versus clopidogrel in major adverse cardiovascular events, mortality, and myocardial infarction.
  • Both ticagrelor and prasugrel were associated with increased bleeding risks, though point estimates for ticagrelor were lower when PLATO was included.

Conclusions:

  • Pooled estimates favoring ticagrelor were substantially influenced by the inclusion of PLATO trial data.
  • The findings suggest a need for additional evidence due to the significant impact of PLATO on risk estimates for dual antiplatelet therapy.
  • Further research is warranted to clarify the comparative effectiveness and safety of these antiplatelet agents.